Neuron-specific Enolase In Diagnosis Research Articles

Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency

Objective: To determine critical reference value (cut-off value) of serum pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase(NSE) in the diagnosis of small cell lung cancer(SCLC). To evaluate the clinical significance of serum levels of ProGRP and NSE in diagnosis and differential diagnosis in SCLC. Methods: Three hundred and fifty-two SCLC patients, 163 non small cell lung cancer(NSCLC)patients , 193 benign pulmonary disease patients and 140 healthy people visiting in National Cancer Hospital were analyzed retrospectively from January 2014 to July 2017.The levels of serum ProGRP and NSE of people were determined using electrochemiluminescent immunoassay respectively . Reference value ranges of the makers were determined by using the method of ROC curves. Results: In NSCLC group, benign lung disease group, healthy control group and mixed group (NSCLC+ lung benign diseases+ healthy control group) as a reference, the cut-off values were 58.3, 62.3, 57.8, 61.3 ng/L. In the diagnosis and differential diagnosis of SCLC and NSCLC, benign lung diseases, healthy controls and mixed group, AUC of ProGRP was 0.940 (0.919-0.961), 0.941 (0.921-0.960), 0.959 (0.944-0.975), 0.946 (0.928-0.963) respectively. The sensitivities of ProGRP were 86.4%, 84.9%, 86.4% and 84.7% respectively. The specificities of ProGRP were 95.7%, 96.9%, 99.3%, 98% respectively. In all groups the Youden's index of ProGRP and NSE were 0.821 vs 0.612, 0.818 vs 0.674, 0.857 vs 0.810, 0.827 vs 0.674. In healthy controls, no statistically significant difference was found between ProGRP and NSE (P>0.05) in the diagnosis of AUC. However, in the remaining 3 groups, the ProGRP diagnosis of AUC was significantly greater than that of NSE (P<0.01). Compared with single marker detection, the sensitivity of combined detection of ProGRP and NSE in diagnosis of SCLC increased to 95.5%, 94%, 96.6% and 94% in each group. There was no significant difference between ProGRP and ProGRP+ NSE in the diagnosis of AUC when compared with the NSCLC group and the mixed group (P>0.05). However, when combined with a healthy control group and a benign lung disease group, the ProGRP+ NSE combination was the highest for AUC diagnosis, compared with ProGRP and NSE (P<0.01). In the SCLC ED group serum ProGRP and NSE levels[776.33(3 103.4)ng/L, 52.14(60.59)μg/L]were higher than those in the SCLC LD group[295.59(799.65)ng/L, 23.36(22.97)μg/L], respectively (all P<0.001). The serum ProGRP levels of N0, N1, N2 and N3 in TNM staging were 113.0(343.65), 167.04(724.56), 427.42(1 388.62), 735.99(1 709.95)ng/L respectively (all P<0.001). Serum ProGRP and NSE levels were not statistically different between the sex groups and the age groups (all P>0.05). Conclusion: To establish the cut-off value of serum ProGRP is helpful for the diagnosis and differential diagnosis of SCLC.

Clinical values of detection of serum levels of S100B and NSE in diagnosis of brain injuries at early period after cardiopulmonary bypass

To investigate the clinical values of detecting the blood serum levels of S100B and neuron-specific enolase (NSE) in diagnosis of brain injuries at early period after cardiopulmonary bypass (CPB). Forty-eight patients with heart disease were divided into 2 groups: CPB group (n = 40) and off-CPB group (n = 8). Before operation, and 24 hours and 48 hours after CPB specimens of peripheral blood were collected and ELISA was used to detect the serum levels of S100B and NSE. Forty-eight hours after the operation brain damage quotient (DQ) was calculated. The serum levels of S100B 24 and 48 hours after operation of the CPB group were 0.61 microg/L +/- 0.18 microg/L and 0.37 microg/L +/- 0.12 microg/L respectively, both significantly higher than that before the operation (0.05 microg/L +/- 0.03 microg/L, P < 0.001). The serum levels of NSE 24 and 48 hours after operation of the CPB group were 10.14 microg/L +/- 3.87 microg/L and 5.77microg/L +/- 2.31 microg/L respectively, both significantly higher than that before operation (2.98 microg/L +/- 1.49 microg/L, P < 0.001). The serum levels of S100B 24 and 48 hours after operation of the off-CPB group were 0.05 microg/L +/- 0.03 microg/L and 0.04 microg/L +/- 0.03 microg/L respectively, both not significantly different from that before operation (0.04 microg/L +/- 0.03 microg/L, P > 0.05). The serum levels of NSE 24 and 48 hours after operation of the off-CPB group were 2.91 microg/L +/- 1.56 microg/L and 2.87 microg/L +/- 1.41 microg/L respectively, both not significantly different from that before operation (2.76 microg/L +/- 1.23 microg/L, P > 0.05). The levels of S100B and NSE 24 hours after CPB were positively correlated with age, CPB time, and cross-clamp time (all P < 0.05). The levels of S100B and NSE 48 hours after CPB were positively correlated with the brain DQ (r = 0.739 P < 0.01, r = 0.371 P < 0.05). The multiple correlation coefficient square (R2) of detection of the levels of both S100B and NSE was 0.851, significantly higher than that of mere detection of S100B (R2 = 0.703) and that of mere detection of NSE (R2 = 0.482) (both P < 0.01). Both serum S100B and serum NSE are sensitive markers in the early diagnosis of brain injuries after CPB. Detection of both S100B and NSE is the most specific, and mere detection of S100B comes behind.

Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease

Neuron-specific enolase (NSE) is among the biochemical markers in cerebrospinal fluid reported to be useful in the differential diagnosis of Creutzfeldt-Jakob disease from other dementing illnesses. In a group of 58 patients with definite and probable Creutzfeldt-Jakob disease, NSE concentrations (median 94·0, interquartile range 256 ng/mL) were significantly higher (p<0·001) than in 26 control patients (9·5, 15·5 ng/mL). At a cut-off of 35 ng/mL an optimum sensitivity of 80% with a specificity of 92% for the diagnosis of Creutzfeldt-Jakob disease by NSE in cerebrospinal fluid was obtained.

Studies of neuron-specific enolase levels in serum and cerebrospinal fluid of children with neurological diseases.

Neuron-specific enolase (NSE) has recently proved to be a useful marker of neuron damage. We determined NSE levels in the serum and CSF of 117 children with various neurological disorders (43 with febrile convulsion, 25 with seizure disorder, 32 with meningitis, 3 with brain tumor, 2 with Reye syndrome, 3 with congenital CNS malformation and 9 with other disorders). The purpose of this study is to assess the potential usefulness of NSE in diagnosis and prognosis. Twenty CSF and serum samples of children without neurological problem served as a control. The mean values of the NSE levels in the CSF and serum of the control group were 5.00 +/- 1.65 ng/ml and 8.34 +/- 4.40 ng/ml respectively. The peak values were found in cases with brain tumor. A patient died of Reye syndrome didn't show a very high level of NSE in the serum or CSF. However, we found significant differences in NSE levels between the patients with febrile convulsions and those with seizure disorders (non-febrile, abnormal EEG). Most of our patients with febrile convulsions were cases of simple febrile convulsion, and their NSE levesin the CSF and serum were 4.55 +/- 1.00 and 8.06 +/- 3.18 ng/ml. Cases with non-febrile seizure disorders had significantly higher level of NSE in both CSF and serum (P less than 0.05). Patients with purulent meningitis usually had higher levels than those with aseptic meningitis. Our study can be summarized thus: 1. A normal level of NSE does not exclude severe neuron damage.(ABSTRACT TRUNCATED AT 250 WORDS)

Significance of neuron-specific enolase in diagnosis of bronchial carcinoma and neuroendocrine tumors

Significance of neuron-specific enolase in diagnosis of bronchial carcinoma and neuroendocrine tumors